ABSTRACT Microwave ablation (MWA) represents a highly effective and clinically significant therapeutic modality for the treatment of liver metastases. The proliferation of disseminated tumor cells within the peri‐necrotic transition zone (TZ) is a critical factor contributing to the postablative recurrence; to date, no effective method has been identified to specifically target and eliminate these cells. Here, based on an experimental liver metastases model, we leverage single‐cell RNA sequencing and flow cytometry analysis, which reveals that TZ exhibits a VEGF‐mediated immunosuppressive microenvironment, characterized by a significant increase of CD155 + myeloid cells. We further report the development of engineered cell membrane vesicles encapsulating Bevacizumab, which are fused with TIGIT‐expressing membranes and platelet membranes (referred to as Bev@TPNVs). The Bev@TPNVs can specifically target the liver and the TZ, inhibit neovascularization, and restore the anti‐tumor functionality of CD8 + T cells. Our findings demonstrate that Bev@TPNVs can effectively suppress liver metastasis after MWA. The intrahepatic metastasis burden is reduced by approximately 10‐fold compared with the control group, and the survival rate of mice within 70 days reaches 50%. This work has the potential to establish a novel standard treatment paradigm that could revolutionize combined immunotherapy following liver metastasis ablation.
Li et al. (Sun,) studied this question.